BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38345158)

  • 1. Immunosuppression and cancer risk in kidney transplant recipients: A retrospective cohort study.
    Sapir-Pichhadze R; Laprise C; Beauchamp ME; Kaouache M; Zhang X; Della Vecchia A; Azoulay L; Franco EL; Abrahamowicz M; Nicolau B
    Int J Cancer; 2024 Jun; 154(12):2043-2053. PubMed ID: 38345158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.
    Wijesinha M; Hirshon JM; Terrin M; Magder L; Brown C; Stafford K; Iacono A
    JAMA Netw Open; 2019 Aug; 2(8):e1910297. PubMed ID: 31461151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of mycophenolate sodium in renal transplant recipients.
    Hiramoto LL; Tedesco-Silva H; Medina-Pestana JO; Felipe CR
    Int J Clin Pharm; 2018 Dec; 40(6):1548-1558. PubMed ID: 30302621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants.
    Okabe Y; Noguchi H; Sato Y; Mei T; Kaku K; Ueki K; Tsuchimoto A; Nakamura M
    Exp Clin Transplant; 2022 Mar; 20(4):362-369. PubMed ID: 35475420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids.
    Cristelli MP; Tedesco-Silva H; Medina-Pestana JO; Franco MF
    Transpl Infect Dis; 2013 Aug; 15(4):369-78. PubMed ID: 23701592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race.
    Soliman KM; Posadas Salas AC; Taber DJ
    Exp Clin Transplant; 2019 Dec; 17(6):707-713. PubMed ID: 30570456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
    de Boer SE; Sanders JSF; Bemelman FJ; Betjes MGH; Burgerhof JGM; Hilbrands L; Kuypers D; van Munster BC; Nurmohamed SA; de Vries APJ; van Zuilen AD; Hesselink DA; Berger SP
    BMC Nephrol; 2021 Jun; 22(1):208. PubMed ID: 34078323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases.
    Kaufman DB; Leventhal JR; Stuart J; Abecassis MM; Fryer JP; Stuart FP
    Transplantation; 1999 Feb; 67(4):586-93. PubMed ID: 10071032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study.
    Krisl A; Stampf S; Hauri D; Binet I; Mueller T; Sidler D; Hadaya K; Golshayan D; Pascual M; Koller M; Dickenmann M; The Swiss Transplant Cohort Study Stcs
    Swiss Med Wkly; 2020 Nov; 150():w20354. PubMed ID: 33277913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes mellitus after kidney transplantation in Japanese patients: The Japan Academic Consortium of Kidney Transplantation study.
    Okumi M; Unagami K; Hirai T; Shimizu T; Ishida H; Tanabe K;
    Int J Urol; 2017 Mar; 24(3):197-204. PubMed ID: 27862344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
    Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
    Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppression in HIV-positive kidney transplant recipients.
    Sorohan BM; Ismail G; Leca N
    Curr Opin Organ Transplant; 2023 Aug; 28(4):279-289. PubMed ID: 37219235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
    Phanish MK; Hull RP; Andrews PA; Popoola J; Kingdon EJ; MacPhee IAM;
    BMC Nephrol; 2020 Mar; 21(1):92. PubMed ID: 32160893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
    Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
    Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.